X0306 4 2022-10-20 1 0001340652 ChemoCentryx, Inc. CCXI 0001423084 Schall Thomas J. C/O CHEMOCENTRYX, INC. 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS CA 94070 1 1 0 0 President and CEO Common Stock 2022-10-20 4 D 0 2393352 D 0 D Stock Option 29.83 2022-10-20 4 D 0 4192 D Common Stock 4192 0 D Stock Option 29.83 2022-10-20 4 D 0 188408 D Common Stock 188408 0 D Stock Option 46.59 2022-10-20 4 D 0 2502 D Common Stock 2502 0 D Stock Option 46.59 2022-10-20 4 D 0 68998 D Common Stock 68998 0 D Stock Option 11.02 2022-10-20 4 D 0 7912 D Common Stock 7912 0 D Stock Option 11.02 2022-10-20 4 D 0 222088 D Common Stock 222088 0 D Stock Option 10.86 2022-10-20 4 D 0 11693 D Common Stock 11693 0 D Stock Option 10.86 2022-10-20 4 D 0 278307 D Common Stock 278307 0 D Stock Option 6.62 2022-10-20 4 D 0 262431 D Common Stock 262431 0 D Stock Option 6.62 2022-10-20 4 D 0 17569 D Common Stock 17569 0 D Stock Option 3.57 2022-10-20 4 D 0 285812 D Common Stock 285812 0 D Stock Option 3.57 2022-10-20 4 D 0 14188 D Common Stock 14188 0 D Stock Option 8.19 2022-10-20 4 D 0 406175 D Common Stock 406175 0 D Stock Option 8.19 2022-10-20 4 D 0 13825 D Common Stock 13825 0 D Stock Option 7.10 2022-10-20 4 D 0 8231 D Common Stock 8231 0 D Stock Option 7.10 2022-10-20 4 D 0 386769 D Common Stock 386769 0 D Stock Option 14.28 2022-10-20 4 D 0 7002 D Common Stock 7002 0 D Stock Option 14.28 2022-10-20 4 D 0 27998 D Common Stock 27998 0 D Restricted Stock Unit 2022-10-20 4 D 0 239934 D Common Stock 239934 0 D Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. /s/ Susan M. Kanaya, as Attorney-in-Fact 2022-10-20